Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of QI-019B in Relapsed/Refractory Multiple Myeloma
NCT07539233Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QI-019B in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 28 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QI-019B
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07539233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539233.